- $946.71m
- $573.59m
US RESEARCH ROUNDUP-Allstate, Caribou Biosciences, Zscaler
U.S. STOCKS ON THE MOVE-Becton Dickinson, Constellation Energy, Marvell
U.S. STOCKS ON THE MOVE-Constellation Energy, AMD
ArriVent falls after lung cancer drug misses late-stage trial goal
NASDAQ RESUMED AT 08:33 AM
ArriVent's cancer pill fails to 'meaningfully' delay disease progression, shares dive (updated)
ArriVent's lung cancer treatment fails late-stage trial
NASDAQ TRADE HALT HALT NEWS PENDING AT 07:55 AM
ArriVent BioPharma, Inc. reports results for the quarter ended June 30 - Earnings Summary
Brief: Arrivent Biopharma Enters Open Market Sale Agreement For Offer And Sell Common Stock Up To $250 Million - SEC Filing
Brief: Arrivent Announces Ind Clearance For Novel Tetravalent Muc16/Napi2b Targeting Adc Arr-002 With Initial Focus In Ovarian And Endometrial Cancers
U.S. RESEARCH ROUNDUP- Arrivent Biopharma, Aveanna Healthcare Holdings, EQT
U.S. RESEARCH ROUNDUP-Aerovironment, Bumble, Lumentum Holdings.
Brief: Arrivent Announces First Patient Dosed In Global Pivotal Phase 3 Alpacca Trial Evaluating Firmonertinib For First-Line Treatment Of EGFR PACC Mutant Non-Small Cell Lung Cancer
Brief: Arrivent Appoints Brent S. Rice As Chief Commercial Officer
Arrivent Biopharma Inc reports results for the quarter ended June 30 - Earnings Summary
Arrivent Biopharma Inc expected to post a loss of 70 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Investar, Steel Dynamics, Axos Financial
U.S. STOCKS ON THE MOVE-Tesla, ABM Industries, Regeneron